Prognostic Factors in Acute Myelogenous Leukemia
Recently, there has been considerable progress in the therapy of acute myelogenous leukemia (AML). Much of this progress results from the use of intensive remission induction (RI) regimens typically consisting of cytarabine and daunorubicin with or without thioguanine In recent studies, individuals who achieve a remission receive intensive post-remission chemotherapy, referred to as consolidation or intensification. Maintenance chemotherapy is also given in some studies.
KeywordsHepatitis Leukemia Creatinine Glucocorticoid Bilirubin
Unable to display preview. Download preview PDF.